Phibro Animal Health Analyst Ratings
Phibro Animal Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/01/2023 | 47.16% | Roth MKM | → $21 | Reiterates | Buy → Buy |
| 08/31/2023 | 19.13% | Morgan Stanley | $18 → $17 | Maintains | Equal-Weight |
| 08/29/2023 | 47.16% | Roth MKM | → $21 | Reiterates | Buy → Buy |
| 07/27/2023 | 26.14% | Morgan Stanley | $18 → $18 | Reiterates | Equal-Weight → Equal-Weight |
| 05/04/2023 | 26.14% | Morgan Stanley | $19 → $18 | Maintains | Equal-Weight |
| 02/09/2023 | 33.15% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight |
| 12/21/2022 | 26.14% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 11/10/2022 | 40.15% | Morgan Stanley | $21 → $20 | Maintains | Equal-Weight |
| 09/16/2022 | 19.13% | Barclays | $22 → $17 | Maintains | Underweight |
| 08/26/2022 | 47.16% | Morgan Stanley | $23 → $21 | Maintains | Equal-Weight |
| 07/25/2022 | 54.17% | Barclays | → $22 | Downgrades | Equal-Weight → Underweight |
| 01/10/2022 | 61.18% | Barclays | → $23 | Upgrades | Underweight → Equal-Weight |
| 11/18/2021 | 61.18% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 07/07/2021 | 61.18% | Barclays | → $23 | Downgrades | Equal-Weight → Underweight |
| 05/13/2021 | 54.17% | Morgan Stanley | $19 → $22 | Maintains | Underweight |
| 05/08/2020 | 61.18% | Credit Suisse | $25 → $23 | Maintains | Neutral |
| 02/06/2020 | — | Gabelli & Co. | Downgrades | Buy → Hold | |
| 01/28/2020 | 61.18% | Barclays | → $23 | Upgrades | Underweight → Equal-Weight |
| 09/05/2019 | 47.16% | Morgan Stanley | $30 → $21 | Upgrades | Underweight → Equal-Weight |
| 08/29/2019 | 26.14% | B of A Securities | $29 → $18 | Reiterates | → Underperform |
| 08/29/2019 | 26.14% | Barclays | $25 → $18 | Maintains | Underweight |
| 08/28/2019 | 75.19% | Credit Suisse | $31 → $25 | Reiterates | → Neutral |
| 06/11/2019 | 75.19% | Barclays | → $25 | Initiates Coverage On | → Underweight |
| 05/09/2019 | — | Gabelli & Co. | Upgrades | Hold → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/01/2023 | 47.16% | 羅斯MKM | →$21 | 重申 | 購買→購買 |
| 2023年08月31日 | 19.13% | 摩根士丹利 | $18→$17 | 維護 | 等重 |
| 2023年08月29日 | 47.16% | 羅斯MKM | →$21 | 重申 | 購買→購買 |
| 07/27/2023 | 26.14% | 摩根士丹利 | $18→$18 | 重申 | 等重→等重 |
| 05/04/2023 | 26.14% | 摩根士丹利 | $19→$18 | 維護 | 等重 |
| 02/09/2023 | 33.15% | 摩根士丹利 | $20→$19 | 維護 | 等重 |
| 2022年12月21日 | 26.14% | 羅斯資本 | →$18 | 開始承保 | →購買 |
| 2022年11月10日 | 40.15% | 摩根士丹利 | $21→$20 | 維護 | 等重 |
| 09/16/2022 | 19.13% | 巴克萊 | $22→$17 | 維護 | 體重不足 |
| 2022年08月26日 | 47.16% | 摩根士丹利 | $23→$21 | 維護 | 等重 |
| 07/25/2022 | 54.17% | 巴克萊 | →$22 | 評級下調 | 等重→減碼 |
| 2022年1月10日 | 61.18% | 巴克萊 | →$23 | 升級 | 重量不足的→等重 |
| 2021年11月18日 | 61.18% | 摩根士丹利 | →$23 | 開始承保 | →等重 |
| 07/07/2021 | 61.18% | 巴克萊 | →$23 | 評級下調 | 等重→減碼 |
| 2021/05/13 | 54.17% | 摩根士丹利 | $19→$22 | 維護 | 體重不足 |
| 05/08/2020 | 61.18% | 瑞士信貸 | $25→$23 | 維護 | 中性 |
| 02/06/2020 | - | 加貝利公司 | 評級下調 | 購買→Hold | |
| 1/28/2020 | 61.18% | 巴克萊 | →$23 | 升級 | 重量不足的→等重 |
| 2019年05月09日 | 47.16% | 摩根士丹利 | $30→$21 | 升級 | 重量不足的→等重 |
| 2019年08月29日 | 26.14% | B of A證券 | $29→$18 | 重申 | →表現不佳 |
| 2019年08月29日 | 26.14% | 巴克萊 | $25→$18 | 維護 | 體重不足 |
| 2019年08月28日 | 75.19% | 瑞士信貸 | $31→$25 | 重申 | →中性 |
| 2019年6月11日 | 75.19% | 巴克萊 | →$25 | 開始承保 | →減持 |
| 2019年05月09日 | - | 加貝利公司 | 升級 | 持有→購買 |
What is the target price for Phibro Animal Health (PAHC)?
Phibro Animal Health(PAHC)的目標價格是多少？
The latest price target for Phibro Animal Health (NASDAQ: PAHC) was reported by Roth MKM on September 1, 2023. The analyst firm set a price target for $21.00 expecting PAHC to rise to within 12 months (a possible 47.16% upside). 9 analyst firms have reported ratings in the last year.
羅斯MKM於2023年9月1日報道了菲布羅動物健康公司(納斯達克：PAHC)的最新目標價。這家分析公司將目標價定為21.00美元，預計PAHC將在12個月內上漲至47.16%(可能上漲47.16%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Phibro Animal Health (PAHC)?
菲布羅動物健康(PAHC)的最新分析師評級是多少？
The latest analyst rating for Phibro Animal Health (NASDAQ: PAHC) was provided by Roth MKM, and Phibro Animal Health reiterated their buy rating.
菲布羅動物健康公司(納斯達克代碼：PAHC)的最新分析師評級由Roth MKM提供，菲布羅動物健康公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Phibro Animal Health (PAHC)?
菲布羅動物健康(PAHC)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phibro Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phibro Animal Health was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與菲布羅動物健康公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。菲布羅動物健康的上一次評級是在2023年9月1日提交的，所以你應該預計下一次評級將在2024年9月1日左右的某個時候公佈。
Is the Analyst Rating Phibro Animal Health (PAHC) correct?
分析師對Phibro Animal Health(PAHC)的評級正確嗎？
While ratings are subjective and will change, the latest Phibro Animal Health (PAHC) rating was a reiterated with a price target of $0.00 to $21.00. The current price Phibro Animal Health (PAHC) is trading at is $14.27, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但菲布羅動物健康(PAHC)的最新評級被重申，目標價在0.00美元至21.00美元之間。Phibro Animal Health(PAHC)目前的交易價格為14.27美元，在分析師的預測範圍內。